Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903

Pain Medicine (United States)

Volumn 13, Issue 11, 2012, Pages 1417-1424

  Atkinson, Thomas M ^a   Halabi, Susan ^b   Bennett, Antonia V ^a   Rogak, Lauren ^a   Sit, Laura ^a   Li, Yuelin ^a   Kaplan, Ellen ^b   Basch, Ethan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer Pain; Measurement; Quality of Life

Indexed keywords

ALKALINE PHOSPHATASE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ACTIVITY PAIN INTERFERENCE; ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PAIN PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RETROSPECTIVE STUDY;

EID: 84869232505     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01498.x     Document Type: Article

References (45)

1. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982;50:1913-1918.
2. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210.
3. Atkinson TM, Mendoza TR, Sit L, etal. The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: Clinical trial endpoint considerations. Pain Med 2010;11:337-346.
4. Yun YH, Mendoza TR, Heo DS, etal. Development of a cancer pain assessment tool in Korea: A validation of a Korean version of the Brief Pain Inventory. Oncology 2004;66:439-444.
5. Klepstad P, Loge JH, Borchgrevink PC, etal. The Norwegian Brief Pain Inventory questionnaire: Translation and validation in cancer pain patients. J Pain Symptom Manage 2002;24:517-525.
6. Radbruch L, Loick G, Kiencke P, etal. Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 1999;18:180-187.
7. Badia X, Muriel C, Gracia A, etal. Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc) 2003;120:52-59.
8. Caraceni A, Mendoza TR, Mencaglia E, etal. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario Per La Valutazione Del Dolore). Pain 1996;65:87-92.
9. Ger L-P, Ho S-T, Sun W-Z, Wang M-S, Cleeland CS. Validation of the Brief Pain Inventory in a Taiwanese population. J Pain 1999;9:105-121.
10. Ballout S, Noureddine S, Huijer HA, Kanazi G. Psychometric evaluation of the Arabic Brief Pain Inventory in a sample of Lebanese cancer patients. J Pain Symptom Manage 2011;42:147-154.
11. Cleeland CS, Ladinsky JL, Serlin RC, Nugyen CT. Multidimensional measurement of cancer pain: Comparison of U.S. and Vietnamese patients. J Pain Symptom Manage 1988;3:23-27.
12. Kalyadina SA, Ionova TI, Ivanova MO, etal. Russian Brief Pain Inventory: Validation and application in cancer pain. J Pain Symptom Manage 2008;35:95-102.
13. Larue F, Colleau SM, Brasseur L, Cleeland CS. Multicentre study of cancer pain and its treatment in France. BMJ 1995;310:1034-1037.
14. Mystakidou K, Mendoza T, Tsilika E, etal. Greek Brief Pain Inventory: Validation and utility in cancer pain. Oncology 2001;60:35-42.
15. Saxena A, Mendoza T, Cleeland CS. The assessment of cancer pain in North India: The validation of the Hindi Brief Pain Inventory-BPI-H. J Pain Symptom Manage 1999;18:27-41.
16. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: The utility of the Japanese Brief Pain Inventory-BPI-J. J Pain Symptom Manage 1998;16:364-373.
17. Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): Its development and use in a study of cancer pain. Pain 1996;67:407-416.
18. Cleeland CS, Nakamura Y, Mendoza TR, etal. Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling. Pain 1996;67:267-273.
19. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133-137.
20. Keller S, Bann CM, Dodd SL, etal. Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309-318.
21. Tittle MB, McMillian SC, Hagan S. Validating the Brief Pain Inventory for use with surgical patients with cancer. Oncol Nurs Forum 2003;30:325-330.
22. Gjeilo KH, Stenseth R, Wahba A, Lydersen S, Klepstad P. Validation of the Brief Pain Inventory in patients six months after cardiac surgery. J Pain Symptom Manage 2007;34:648-656.
23. Williams VSL, Smith MY, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage 2006;31:48-57.
24. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain 2006;10:353-361.
25. Osborne TL, Raichle KA, Jensen MP, Ehde DM, Kraft G. The reliability and validity of pain interference measures in persons with multiple sclerosis. J Pain Symptom Manage 2006;32:217-229.
26. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: Use in medical development to support labeling claims. 2009.
27. Price DD, Harkins SW, Baker C. Sensory-affective relationships among different types of clinical and experimental pain. Pain 1987;28:297-307.
28. Atkinson TM, Rosenfeld BD, Sit L, etal. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage 2011;41:558-565.
29. Dworkin RH, Turk DC, Farrar JT, etal. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
30. Cleeland CS. Research in cancer pain. What we know and what we need to know. Cancer 1991;67:823-827.
31. Browne MW, Cudeck R. Alternative Ways of Assessing Model Fit. Newbury Park, CA: Sage; 1993.
32. Bentler PM. Comparative fit indixes in structural models. Psychol Bull 1990;107:238-246.
33. Hu L, Bentler PM. Cutoff criteria for fit indices in covariance structure analysis: Conventional criteria vs new alternatives. Struct Equ Modeling 1999;6:1-55.
34. Dolan CV, Molenaar PC. Testing specific hypotheses concerning latent group differences in multi-group covariance structure analysis with structured means. Multivariate Behav Res 1994;29:203-222.
35. Small EJ, Halabi S, Ratain MJ, etal. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol 2002;20:3369-3375.
36. Bok RA, Halabi S, Fei DT, etal. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res 2001;15:2533-2536.
37. Kantoff PW, Halabi S, Farmer DA, etal. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 2001;19:3025-3028.
38. George DJ, Halabi S, Shepard TF, etal. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 9480. Clin Cancer Res 2005;11:1815-1820.
39. George DJ, Halabi S, Shepard TF, etal. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-1936.
40. Taplin M-E, George DJ, Halabi S, etal. Prognostic significance of plasma chromogranin A Levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386-391.
41. Humphrey PA, Halabi S, Picus J, etal. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 150005/9480. Clin Genitourin Cancer 2006;4:269-274.
42. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff P. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583. J Clin Oncol 2003;21:490-495.
43. Loehlin JC. Latent Variable Models: An Introduction to Factor, Path, and Structural Equation Analysis, 4th edition. Mahwah, NJ: Lawrence Erlbaum Associates, Inc.; 2004.
44. Ahles TA, Herndon JE, Small EJ, etal. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of Intergroup 0159/Cancer and Leukemia Group B 9480. Cancer 2004;101:2202-2208.
45. Halabi S, Vogelzang NJ, Kornblith AB, etal. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;15:2544-2549.